Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$573M |
| 2 |
Microsoft
MSFT
|
+$529M |
| 3 |
McDonald's
MCD
|
+$469M |
| 4 |
Walt Disney
DIS
|
+$303M |
| 5 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$291M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$482M |
| 2 |
Comcast
CMCSA
|
+$481M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$381M |
| 4 |
Sherwin-Williams
SHW
|
+$374M |
| 5 |
CELG
Celgene Corp
CELG
|
+$341M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 56.22% |
| 2 | Technology | 7.41% |
| 3 | Consumer Discretionary | 6.04% |
| 4 | Financials | 5.89% |
| 5 | Industrials | 4.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
6651
Minerva Neurosciences
NERV
$158M
| $110K | ﹤0.01% |
+1,690
| New | +$131K |
2017 Q1
0 quarters
|
|
|
GNCA
6652
CALL
DELISTED
Genocea Biosciences, Inc.
GNCA
| $110K | ﹤0.01% |
+2,250
| New | +$87.9K |
2017 Q1
0 quarters
|
|
6653
Grupo Aval
AVAL
$5.92B
| $109K | ﹤0.01% |
+13,371
| New | +$108K |
2017 Q1
0 quarters
|
|
6654
Gladstone Capital
GLAD
$435M
| $109K | ﹤0.01% |
+5,733
| New | +$107K |
2017 Q1
0 quarters
|
|
6655
Novavax
NVAX
$1.83B
| $109K | ﹤0.01% |
4,279
+2,820
| +193% | +$77.5K |
2013 Q2
15 quarters
|
|
|
PZN
6656
DELISTED
Pzena Investment Management, Inc. Class A
PZN
| $109K | ﹤0.01% |
11,107
-3,551
| -24% | -$36K |
2016 Q3
2 quarters
|
|
|
OMED
6657
CALL
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $109K | ﹤0.01% |
11,800
-5,600
| -32% | -$49.2K |
2016 Q4
1 quarter
|
|
6658
PUT
Arcos Dorados Holdings
ARCO
$1.7B
| $108K | ﹤0.01% |
+13,773
| New | +$85K |
2017 Q1
0 quarters
|
|
6659
PUT
Cerus
CERS
$468M
| $108K | ﹤0.01% |
24,300
-13,100
| -35% | -$55.5K |
2013 Q4
13 quarters
|
|
|
HDSN
6660
Hudson Technologies
HDSN
$219M
| $108K | ﹤0.01% |
16,376
-5,189
| -24% | -$37.8K |
2016 Q4
1 quarter
|
|
6661
PUT
INNOVATE Corp
VATE
$98.6M
| $108K | ﹤0.01% |
+1,740
| New | +$108K |
2017 Q1
0 quarters
|
|
|
HIVE
6662
DELISTED
Aerohive Networks
HIVE
| $108K | ﹤0.01% |
+25,563
| New | +$128K |
2017 Q1
0 quarters
|
|
|
EPE
6663
PUT
DELISTED
EP Energy Corporation
EPE
| $108K | ﹤0.01% |
22,700
-11,500
| -34% | -$58.9K |
2016 Q2
3 quarters
|
|
|
TESO
6664
DELISTED
Tesco Corp
TESO
| $108K | ﹤0.01% |
+13,434
| New | +$114K |
2017 Q1
0 quarters
|
|
6665
CALL
Harmonic Inc
HLIT
$1.22B
| $107K | ﹤0.01% |
+18,000
| New | +$98.7K |
2017 Q1
0 quarters
|
|
|
NSLR
6666
PUT
Neostellar Capital Corp
NSLR
$199M
| $107K | ﹤0.01% |
28,472
-4,288
| -13% | -$18.7K |
2016 Q2
3 quarters
|
|
|
ATHX
6667
DELISTED
Athersys, Inc. Common Stock
ATHX
| $107K | ﹤0.01% |
2,498
+1,909
| +324% | +$61K |
2016 Q4
1 quarter
|
|
|
JE
6668
DELISTED
Just Energy Group Inc
JE
| $107K | ﹤0.01% |
516
-1,151
| -69% | -$221K |
2014 Q2
11 quarters
|
|
|
FRSH
6669
DELISTED
Papa Murphy's Holdings, Inc
FRSH
| $107K | ﹤0.01% |
+22,534
| New | +$97.4K |
2017 Q1
0 quarters
|
|
|
SNAK
6670
CALL
DELISTED
Inventure Foods, Inc.
SNAK
| $107K | ﹤0.01% |
+24,100
| New | +$145K |
2017 Q1
0 quarters
|
|
6671
CALL
Collegium Pharmaceutical
COLL
$713M
| $105K | ﹤0.01% |
+10,400
| New | +$155K |
2017 Q1
0 quarters
|
|
|
HIO
6672
Western Asset High Income Opportunity Fund
HIO
$309M
| $105K | ﹤0.01% |
+20,833
| New | +$106K |
2017 Q1
0 quarters
|
|
6673
Lineage Cell Therapeutics
LCTX
$237M
| $105K | ﹤0.01% |
34,820
-27,420
| -44% | -$77.9K |
2016 Q4
1 quarter
|
|
|
NPTN
6674
CALL
DELISTED
NEOPHOTONICS CORP
NPTN
| $105K | ﹤0.01% |
+11,700
| New | +$122K |
2017 Q1
0 quarters
|
|
|
CGI
6675
PUT
DELISTED
Celadon Group Inc
CGI
| $105K | ﹤0.01% |
+16,000
| New | +$131K |
2017 Q1
0 quarters
|
|
Similar funds
Citadel Advisors's Q1 2017 Portfolio in Review
As of Q1 2017, Citadel Advisors held 8,634 positions worth $109B, up 11% from $99B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Citadel Advisors deployed $4.43B of net new capital in Q1 2017, opening 1,445 new positions and adding to 2,647 existing holdings. Its largest new stake was Meta Platforms (Facebook): 4,289,917 shares worth $609M.
By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, down from 63% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Alphabet (Google) Class A, an estimated $482M trimmed.
- Citadel Advisors's largest Q1 2017 buy was Meta Platforms (Facebook): 4,289,917 shares worth $609M.
- Citadel Advisors added most to Microsoft in Q1 2017, an estimated $529M increase.
- Citadel Advisors's biggest Q1 2017 reduction was Alphabet (Google) Class A, cutting an estimated $482M.
- Citadel Advisors fully exited Celgene Corp in Q1 2017, selling an estimated $341M.
- Citadel Advisors's ten largest holdings make up 19% of its $109B portfolio in Q1 2017.
- Citadel Advisors opened 1,445 new positions and closed 1,267 in Q1 2017.
- Citadel Advisors's portfolio value rose 11% quarter-over-quarter to $109B.
Based on Citadel Advisors's 13F filing for Q1 2017, filed 12 May 2017.